When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Daratumumab - Wikipedia

   en.wikipedia.org/wiki/Daratumumab

   Treatment of multiple myeloma with daratumumab potentially increases the patient's susceptibility to bacterial and viral infections, due to the killing of natural killer cells (which are the main innate immune system defense against virus). [16] Daratumumab frequently causes human cytomegalovirus (CMV) reactivation by an unknown mechanism. [17]

3. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source , are explained in Nomenclature of monoclonal antibodies .

4. Daratumumab/hyaluronidase - Wikipedia

   en.wikipedia.org/wiki/Daratumumab/hyaluronidase

   It was approved for use in the United States in May 2020. [2] [7] [8]Efficacy of daratumumab and hyaluronidase-fihji (monotherapy) was evaluated in the COLUMBA trial (NCT03277105), an open-label non-inferiority trial randomizing 263 participants to daratumumab and hyaluronidase-fihj and 259 to intravenous daratumumab (daratumumab IV). [2]

5. Breakthrough antidepressants with fewer side effects could ...

   www.aol.com/finance/breakthrough-antidepressants...

   KOR antagonists, in fact, are the focus of research into treatment for depression, anxiety, and substance use disorders. The idea is that these drugs seem to blunt the effects of the stress that ...

6. Management of depression - Wikipedia

   en.wikipedia.org/wiki/Management_of_depression

   The risk factors [110] for treatment resistant depression are: the duration of the episode of depression, severity of the episode, if bipolar, lack of improvement in symptoms within the first couple of treatment weeks, anxious or avoidant and borderline comorbidity and old age. Treatment resistant depression is best handled with a combination ...

7. FDA approves standalone use of J&J’s ketamine-derived ... - AOL

   www.aol.com/fda-approves-standalone-j-j...

   The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the ...